- Stocks
- Pharma & Healthcare
- Wanbury
Wanbury share price
NSE: WANBURYPharma & HealthcareDrug Manufacturers - Specialty & Generic
Wanbury at a glance
Wanbury (NSE: WANBURY) closed at ₹185.66 on 22 Oct 2026, down 0.42% on the day. With a market capitalisation of ₹649 Cr, it ranks 1657th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 9.6× trailing earnings, against a return on equity of 51.5% in FY25. Over the past year the share price has fallen 25.7%. Its 52-week range is ₹161.50 (27 Jan 2026) to ₹358.85 (15 Jul 2026); the last close is 48.3% below the high. In Q1 FY26, the quarter ended 30 Jun 2025, revenue was ₹163 Cr (+24.5% year on year) and net profit ₹13 Cr (+1,197.1%), on a consolidated basis. Promoters held 43.02% of the company as of 30 Jun 2026; 86.69% of promoter shares were pledged.
Key numbers
- Market cap
- ₹649 CrRank 1657 on NSE
- P/E (trailing)
- 9.6×
- Price to book
- 12.97×FY25
- EPS (TTM)
- ₹13.12to Q1 FY26
- ROE
- 51.5%FY25
- ROCE
- 27.8%FY25
- Debt to equity
- 2.92FY25
- Net profit margin
- 5.1%FY25
- Book value / share
- ₹18.09FY25
- 52-week high
- ₹358.8515 Jul 2026
- 52-week low
- ₹161.5027 Jan 2026
- 1-year return
- −25.7%
- RSI (14-day)
- 31.4
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.42% | −2.5% | −18.4% | −43.9% | −25.7% |
Wanbury quarterly results
| Quarter | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹144 Cr | ₹146 Cr | ₹139 Cr | ₹131 Cr | ₹161 Cr | ₹133 Cr | ₹172 Cr | ₹163 Cr |
| Revenue YoY | +16.5% | +15.7% | +4.8% | −10.4% | +11.6% | −8.3% | +23.4% | +24.5% |
| Net profit | ₹7 Cr | ₹10 Cr | ₹34 Cr | ₹1 Cr | ₹8 Cr | ₹1 Cr | ₹20 Cr | ₹13 Cr |
| Net profit YoY | — | — | +3,197.1% | −77.8% | +9.0% | −88.1% | −39.8% | +1,197.1% |
| Net margin | 5.1% | 7.1% | 24.1% | 0.8% | 5.0% | 0.9% | 11.8% | 8.3% |
| EPS | ₹2.25 | ₹3.13 | ₹10.28 | ₹0.32 | ₹2.44 | ₹0.38 | ₹6.18 | ₹4.12 |
Wanbury financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹367 Cr | ₹393 Cr | ₹511 Cr | ₹500 Cr | ₹576 Cr | ₹600 Cr |
| Operating profit | −₹18 Cr | −₹12 Cr | ₹5 Cr | −₹10 Cr | ₹31 Cr | ₹30 Cr |
| Net profit | ₹64 Cr | −₹13 Cr | ₹81 Cr | −₹10 Cr | ₹56 Cr | ₹31 Cr |
| EPS (₹) | ₹27.00 | −₹5.00 | ₹25.00 | −₹3.00 | ₹17.00 | ₹9.00 |
| Cash from operations | ₹44 Cr | ₹17 Cr | ₹41 Cr | ₹20 Cr | ₹4 Cr | ₹26 Cr |
| Total debt | ₹100 Cr | ₹72 Cr | ₹0 Cr | ₹0 Cr | ₹82 Cr | ₹160 Cr |
| Shareholders' equity | −₹143 Cr | −₹156 Cr | −₹23 Cr | −₹33 Cr | ₹28 Cr | ₹59 Cr |
Wanbury shareholding pattern
| Holder | 30 Jun 2025 | 18 Sep 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 39.63% | 43.09% | 39.63% | 43.07% | 43.02% | 43.02% |
| Foreign institutions | 1.59% | 0.82% | 0.81% | 0.72% | 0.59% | 0.89% |
| Domestic institutions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.06% |
| Non-institutions | 58.78% | 56.08% | 59.56% | 56.21% | 56.39% | 56.03% |
| Promoter shares pledged | 76.74% | 86.67% | 71.73% | 86.67% | 86.69% | 86.69% |
Wanbury vs peers
The listed Pharma & Healthcare companies nearest to Wanbury by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KILITCHKilitch Drugs (India) | ₹215.00 | −0.92% | +22.8% | ₹752 Cr | 24.2 | — |
| VIKRAMTHVikram Thermo | — | — | — | ₹728 Cr | — | — |
| ZIMLABZim Laboratories | ₹133.50 | +2.30% | +92.4% | ₹715 Cr | 112.2 | — |
| VALIANTLABValiant Laboratories | ₹131.05 | −2.00% | +56.4% | ₹712 Cr | — | — |
| AMANTAAmanta Healthcare | ₹182.55 | −3.26% | +37.4% | ₹709 Cr | 42.2 | — |
| GAUDIUMIVFGaudium IVF and Women Health | ₹95.11 | +1.07% | — | ₹692 Cr | 24.3 | — |
| WANBURYWanbury | ₹185.66 | −0.42% | −25.7% | ₹649 Cr | 9.6 | — |
Ask anything about Wanbury
Pivot answers on the live chart with evidence you can check, and tests strategies against WANBURY's own history. Try: “Why has WANBURY moved over the last three months?” · “Backtest a 50-day moving-average crossover on WANBURY over five years” · “Compare WANBURY with KILITCH on margins and valuation”
Frequently asked questions about Wanbury
What is the share price of Wanbury today?
Wanbury (NSE: WANBURY) last closed at ₹185.66 on 22 Oct 2026. Its 52-week high is ₹358.85 and its 52-week low is ₹161.50.
What is the market cap of Wanbury?
Wanbury's market capitalisation is ₹649 Cr (₹649 Cr) at the 22 Oct 2026 close, ranking 1657th among the NSE companies Pivot tracks.
What is the P/E ratio of Wanbury?
Wanbury trades at a trailing P/E of 9.6. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 42.2.
What is the ROE and ROCE of Wanbury?
Return on equity was 51.5% in FY25 and return on capital employed was 27.8% in FY25 (consolidated figures).
Is Wanbury a debt-free company?
No. Wanbury's debt-to-equity ratio was 2.92 in FY25, with total debt of ₹160 Cr.
What were Wanbury's latest quarterly results?
For Q1 FY26 (quarter ended 30 Jun 2025), Wanbury reported revenue of ₹163 Cr, +24.5% year on year, and net profit of ₹13 Cr, +1,197.1% year on year.
How has Wanbury stock performed over the last year?
Wanbury's share price has fallen 25.7% over the past year, −43.9% over three months and −18.4% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Wanbury?
As of 30 Jun 2026: promoters 43.02%, foreign institutions 0.89%, domestic institutions 0.06%, non-institutions 56.03%. 86.69% of promoter shares were pledged.
Who are Wanbury's competitors?
The listed Pharma & Healthcare companies closest to Wanbury by market cap are Kilitch Drugs (India), Vikram Thermo, Zim Laboratories, Valiant Laboratories, Amanta Healthcare and Gaudium IVF and Women Health.
Is Wanbury a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Wanbury's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on WANBURY against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with W · all NSE stocks · this page as text